Supplemental Online Content

Louvet A, Labreuche J, Dao T, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. *JAMA*. Published May 9, 2023. doi:10.1001/jama.2023.4902

eAppendix. Supplemental Methods

eTable 1. Major Deviations in the Two Groups

eTable 2. Reasons for Treatment Interruption in the Two Groups

eTable 3. Causes of Death in the Two Groups During the 6-Month Follow-up

eTable 4. Distribution of Infection Occurring in the First 60 Days in the Two Groups

eTable 5. Total Number of Serious Adverse Events Reported Within the First 6 Months (End of Follow-up) in the Two Groups

eTable 6. Adverse Drug Reactions Reported in the Safety Population (n=141 in the Experimental Arm and n=143 in the Placebo Arm) up to 2 Months

eTable 7. Sensitivity Analyses on All-Cause Mortality at 2-, 3 and 6-Months

eTable 8. Comparison in Alcohol Relapse During the 180-Day Follow-up Between the Two Study Groups

eTable 9. Serious Adverse Events Reported in the Safety Population During the First 60 Days of Follow-up (Primary Endpoint)

eFigure 1. Treatment Effect Size on 60-Day Survival (Primary Outcome) According to Treated Infection at Baseline

eFigure 2. Cumulative Incidence of Alcohol Relapse During the 180-Day Follow-up Estimated Using Kalbfleisch and Prentice by Treating Death as Competing Event

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix. Supplemental Methods

Patient selection

Patients could not have a past history of allergy of hypersensitivity to amoxicillin or clavulanate, type 1 hepatorenal syndrome before the initiation of treatment, uncontrolled gastrointestinal bleeding or untreated infection. In case of evidence of bacterial sepsis at admission, infection had to be cured by antibiotics and a therapeutic window of at least 7 days was required before entering the trial. Carriage of HCV RNA and HBsAg were also exclusion criteria.

Sample calculation

The sample size was calculated for a total of 54 events (death) based on the expected primary outcome rate of 73% in patients treated by prednisolone, and assuming an absolute increase of 14% (target effect size) with combined prednisolone and antibiotics (resulting in a primary outcome of 87% in the amoxicillin/clavulanate group), with a follow-up of 60 days in all patients and a 5% rate of loss to follow-up. A French multicenter trial (Mathurin et al. JAMA 2013) observed that patients with a baseline MELD score \geq 21 had an 18.8% decrease in 2-month survival compared to patients with a MELD score <21. The target effect size was determined by an expected difference of 75% of the difference in estimated two-month survival in patients with severe AH with a MELD score <21 (91.8%) versus those with MELD \geq 21 (73.0%) (Mathurin et al. JAMA 2013). Details are presented in the trial protocol (Supplement 1).

Calculation of diagnostic and prognostic scores

The Lille score was calculated at day 7 and the MELD score was calculated at each visit. The Maddrey discriminant function and the MELD score were calculated at baseline, and the Lille model was calculated 7 days after treatment had begun. The formulas for the scores were as follows: Maddrey discriminant function = $4.6 \times [\text{patient prothrombin time} - \text{control prothrombin time} (in seconds)] + serum bilirubin (in mg/dL); MELD score = <math>[9.57 \times \text{loge creatinine} (in mg/dL) + 3.78 \times \text{loge bilirubin} (in mg/dL) + 11.20 \times \text{loge INR} + 6.43];$ Lille score = Exp(-R)/[1+Exp(-R)], where R = $[3.19 - 0.101 \times \text{age} (in years}) + 0.147 \times \text{albumin} (in g/L) + 0.0165 \times \text{evolution} in bilirubin (in µmol/L) - 0.206 \times \text{renal insufficiency} -0.0065 \times \text{bilirubin} (in µmol/L) - 0.0096 \times \text{prothrombin} time (in seconds)].$

Safety report

Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) terminology, version 24.0, by System Organ Class (SOC) and preferred terms. Seriousness and causal relationship were assessed by the investigators. All adverse and serious adverse events were reported to the Cellule Vigilance des Essais Cliniques, Centre Hospitalier Universitaire de Lille. Serious adverse events were reported within the first 24 hours and closely monitored. A causal relationship was assessed by both the investigator and the sponsor. An independent data and safety monitoring board (DSMB) was set up to review all serious adverse events.

eTable 1. Major Deviations in the Two Groups

These patients were excluded from the sensitivity analysis restricted to patients treated according to study protocol

Major deviation	Amoxicillin/clavulanate group	Placebo group
	n=10	n=8
Received the non-allocated intervention	7	6
Received steroids within the last 6 months	1	0
Did not receive any treatment	1	0
Failure of transjugular liver biopsy	1	0
Liver biopsy did not confirm AH	0	1
Ongoing candidiasis at inclusion	0	1

eTable 2. Reasons for Treatment Interruption in the Two Groups

Experimental treatment interruption	A/C* (n=141)	P* (n=143)	Total (n=284)			
All treatment interruptions	19	36	55			
Interruption of amoxicillin/clavulana	te or placebo and	prednisolone				
Treatment stopped	14	29	43			
Both drugs temporarily interrupted	2	9	11			
Both drugs withdrawn	12	20	32			
Interruption of amoxicillin/clavulanate or placebo only*						
Treatment stopped	5	6	11			
Augmentin/placebo temporarily interrupted	3	1	4			
Augmentin/placebo withdrawn	2	5	7			
Interruption of predn	isolone only**					
Treatment stopped	0	1	1			
Prednisolone temporarily interrupted	0	0	0			
Prednisolone withdrawn	0	1	1			

*A/C is for amoxicillin/clavulanate, P is for placebo

eTable 3. Causes of Death in the Two Groups During the 6-Month Follow-up

	Amoxicillin/clavulanate + prednisolone group (43 deaths)	Placebo + prednisolone group (48 deaths)
Hepatic insufficiency	17	11
Gastrointestinal bleeding	7	12
Hepatorenal syndrome	1	3
Encephalopathy	3	3
Infection (pneumonia)	10 (7)	13 (5)
Cardiovascular event	1	2
Cancer	1	0
Unknown	3	4

eTable 4. Distribution of Infection Occurring in the First 60 Days in the Two Groups

Site of infection	Amoxicillin/clavulanate + prednisolone n=42	Placebo + prednisolone n=59
	11=42	11=59
Lung infection	16	16
Spontaneous bacterial peritonitis	3	10
Bacteremia	5	8
Urinary tract infection	4	10
Skin infection	1	5
C. difficile infection	1	2
Other infections	12	8

eTable 5. Total Number of Serious Adverse Events Reported Within the First 6 Months (End of Follow-up) in the Two Groups

	۸	lumber of patient	ts	1	Number of events	
Classification	Augmentin	Placebo	Total	Augmentin	Placebo	Total
All Serious Adverse Events	92	102	194	164	211	375
Hepatobiliary disorders	51	44	95	59	61	120
Hepatic failure (including acute hepatic failure, hepatic encephalopathy, ascites, jaundice, abnormal hepatic tests, hydrothorax, new occurrence of alcoholic hepatitis, hepatopulmonary syndrome)	42	37	79	48	52	100
Hepatorenal syndrome	9	9	18	10	9	19
Liver nodule compatible with hepatocellular carcinoma	1	0	1	1	0	1
Drug-induced liver injury	0	0	0	0	0	0
Infections	25	47	72	35	60	95
Pneumonia	6	12	18	6	13	19
Pneumocystis jirovecii pneumonia	8	7	15	8	7	15
Bacteremia	2	11	13	2	11	13
Spontaneous bacterial peritonitis	3	9	12	3	12	15
Skin and joint infection	5	4	9	5	4	9
Septic shock	2	6	8	2	6	8
Urinary tract infection	2	3	5	2	3	5
Clostridium difficile infection	1	3	4	2	3	5
Fungal infection	2	1	3	2	1	3
Other infection	2	0	2	3	0	3
Gastrointestinal disorders	18	27	45	19	29	48
Gastrointestinal hemorrhage	17	24	41	18	25	43
Other (diarrhoea, intestinal obstruction)	1	4	5	1	4	5
General disorders (e.g. general physical health deterioration, fever without sepsis)	12	6	18	12	6	18
Metabolic and endocrine disorders	5	7	12	5	9	14
Psychiatric disorders	9	12	21	11	13	24
Acute renal failure not related to HRS	5	6	11	6	6	12
Surgical and medical procedures (liver transplantation)	5	7	12	5	7	12

Cardiac disorders	2	3	5	2	3	5
Cardiac failure	1	1	2	1	1	2
Tachycardia	1	0	1	1	0	1
Cardiac arrest	0	1	1	0	1	1
Myocardial infarction	0	1	1	0	1	1
Vascular disorders	2	3	5	2	4	6
Neoplasms	2	3	5	2	3	5
Blood and lymphatic system disorders	1	4	5	1	4	5
Anaemia related to cirrhosis	1	3	4	1	3	4
Neutropenia	0	1	1	0	1	1
Nervous system disorders	1	1	2	1	1	2
Injury and procedural complications	1	3	4	1	3	4
Fall	0	1	1	0	1	1
Post procedural haemorrhage	0	1	1	0	1	1
Respiratory, thoracic and mediastinal disorders	1	0	1	1	0	1
Pulmonary embolism	1	0	1	1	0	1
Skin and subcutaneous tissue disorders	0	1	1	0	1	1
Drug eruption	0	1	1	0	1	1

eTable 6. Adverse Drug Reactions Reported in the Safety Population (n=141 in the Experimental Arm and n=143 in the Placebo Arm) up to 2 Months

*Only one episode of diarrhoea in one patient treated with antibiotics was reported as an adverse drug reaction after the first month. All other adverse drug reactions were reported within the first month.

	1	Number of patier	nts	Number of adverse drug reactions		
Classification	АТВ	PLB	Total	АТВ	PLB	Total
All adverse drug reactions	29	20	49	36	23	59
Gastrointestinal disorders	26	17	43	31	20	51
Diarrhoea*	20	17	37	23	17	40
Abdominal pain	4	2	6	4	2	6
Nausea	1	0	1	2	0	2
Vomiting	2	1	3	2	1	3
Infections and infestations	2	1	3	2	1	3
Clostridium difficile infection	1	1	2	1	1	2
Gastrointestinal fungal infection	1	0	1	1	0	1
Metabolism and nutrition disorders	1	0	1	1	0	1
Hypokaliemia	1	0	1	1	0	1
Skin and subcutaneous disorders	2	2	4	2	2	4
Toxic skin eruption	0	2	2	0	2	2
Pruritus	2	0	2	2	0	2

eTable 7. Sensitivity Analyses on All-Cause Mortality at 2-, 3 and 6-Months

	Amoxicillin/clavulanate +	Placebo +		Absolute difference	Hazard ratio
	prednisolone	prednisolone	P-Value	(CI)	(CI)
nalysis restricted to patients treated acc	cording to study protocol				
60-day mortality (primary outcome)	23/132 (17.8)	30/134 (22.5)	0.35	-4.7 (-14.4 to 5.1)	0.77 (0.44 to 1.34
90-day mortality	27/132 (21.0)	36/134 (27.1)	0.27	-6.1 (-16.5 to 4.3)	0.75 (0.45 to 1.25
180-day mortality	38/132 (29.8)	45/134 (34.2)	0.41	-4.4 (-16.0 to 7.0)	0.84 (0.54 to 1.29
ver transplantation-free survival analysi	is (LTFS)				
60-day LTFS	28/142 (19.8)	33/142 (23.2)	0.51	-3.5 (-13.0 to 6.2)	0.84 (0.50 to 1.40
90-day LTFS	34/142 (24.0)	42/142 (29.6)	0.33	-5.5 (-15.9 to 4.8)	0.80 (0.50 to 1.26
180-day LTFS	48/142 (33.3)	55/142 (38.8)	0.41	-4.7 (-16.0 to 6.5)	0.85 (0.57 to 1.26

Values are n/N (Kaplan-Meier estimates, %)

eTable 8. Comparison in Alcohol Relapse During the 180-Day Follow-up Between the Two Study Groups

	Amoxicillin/clavulanate +	vulanate + Placebo +		SHR (95%CI)
	prednisolone	prednisolone		
Alcohol relapse	38/142 (27.4)	35/142 (25.1)	0.69	1.10 (0.69 to 1.74)
Among patients with Alcohol	relapse			
Time from first relapse				
Median (Q1-Q3) , day	35 (15; 79)	36 (10; 58)		
Alcohol dose, g	35 (20; 75)	35 (10; 60)		

SHR indicated subhazard of alcohol relapse estimated using univariable Fine & Gray model treating death as a competing event.

By treating the first alcohol relapse as a time-dependent covariate into the Cox's regression model, the treatment effect size remained unchanged, with an HR for amoxicillin/clavulanate group vs. placebo group of 0.77 (95%Cl, 0.45 to 1.32, p=0.34) at 60 days, 0.78 (95%Cl, 0.47 to 1.27, p=0.31) at 90 days and 0.88 (95%Cl, 0.58 to 1.32, p=0.52) at 180 days.

eTable 9. Serious¹ Adverse Events Reported in the Safety Population² During the First 60 Days of Follow-up (Primary Endpoint)

	Number	of patients	Number of events		
Classification	Amoxicillin- clavulanate (n=141)	Placebo (n=143)	Amoxicillin- clavulanate	Placebo	
Surgical and medical procedures (liver transplantation)	4	2	4	2	
Cardiac disorders	2	3	2	3	
Cardiac failure	1	2	1	2	
Tachycardia	1	0	1	0	
Myocardial infarction	0	1	0	1	
Vascular disorders	2	2	2	2	
Neoplasms	2	1	2	1	
Blood and lymphatic system disorders	0	2	0	2	
Anaemia related to cirrhosis	0	2	0	2	
Nervous system disorders	1	1	1	1	
Injury and procedural complications	0	2	0	2	
Fall	0	1	0	1	
Post procedural haemorrhage	0	1	0	1	
Respiratory, thoracic and mediastinal disorders	1	0	1	0	
Pulmonary embolism	1	0	1	0	
Skin and subcutaneous tissue disorders	0	1	0	1	

© 2023 American Medical Association. All rights reserved.


Drug eruption	0	1	0	1	
Severe adverse events reported out to 6 months are displayed in Supplemental Table 5. Adv	verse drug reac	tions reported	up to 2 months	are displayed in	n Supplemental

Table 6.

¹ Seriousness criteria as defined by ICH guidelines and EU Clinical Trial Directive (2001/20/EC): any adverse event that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is considered as clinically significant by the investigator.

² Safety population: treatment arm as defined by the treatment actually taken by the patient, independently from the arm they were randomized in

eFigure 1. Treatment Effect Size on 60-Day Survival (Primary Outcome) According to Treated Infection at Baseline



© 2023 American Medical Association. All rights reserved.

eFigure 2. Cumulative Incidence of Alcohol Relapse During the 180-Day Follow-up Estimated Using Kalbfleisch and Prentice by Treating Death as Competing Event

